GlucoLight Awarded Patent for Tissue Oximetry Measurement Technology

2008-04-25 15:37:16 -

www.GlucoLight.com - GlucoLight Corporation, a development stage company focused on the non-invasive, continuous measurement of blood glucose levels, today announced that it has been awarded US Patent No. 7,356,365 for the non-invasive method and apparatus of measuring tissue oximetry. The patent was assigned to the company effective April 8, 2008.

The patent, granted to GlucoLight's Chief Technology Officer and

co-founder, Matthew Schurman, Ph.D., uses infrared light to measure oxygenation of blood in human tissue. This method uses optical coherence tomography (OCT), which GlucoLight has also used to develop non-invasive, continuous glucose measurement technology, and its first product SENTRIS-100(TM).

The oxygenation of blood perfused tissue is measured by shining light into the perfused tissue and analyzing the light reflected within the tissue. The light is reflected by cell walls in the tissue and is partially absorbed by hemoglobin in the blood. Since the extent of absorption is sensitive to the extent of hemoglobin oxygenation, measurement and processing of the reflected light provides a measure of the oxygenation of the blood.

GlucoLight is conducting additional clinical trials of its SENTRIS-100(TM) monitor in the second and third quarters of 2008.

About GlucoLight Corporation

Formed in 2003, GlucoLight is a development-stage company focused on continuous, non-invasive blood glucose monitoring in the acute care environment.

Using Optical Coherence Tomography (OCT) based technology, GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels. GlucoLight's Sentris-100(TM) monitor samples these physiological targets every two minutes to accurately track blood glucose levels.

GlucoLight's Sentris-100(TM) monitor is the only continuous, non-invasive blood glucose monitor for the acute care environment that is in clinical trials.

For more information, visit www.GlucoLight.com.

GlucoLight Corporation
Ray Krauss
Chief Executive Officer
484-893-5132 x700
Ray@GlucoLight.com
or
Media:
Gregory FCA
Matt McLoughlin
Senior Account Executive
610-642-8253 x129
Matt@gregoryfca.com